Sulfonylureas and mortality in diabetic patients after myocardial infarction.
Brady
P A
PA
Al-Suwaidi
J
J
Kopecky
S L
SL
Terzic
A
A
D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D015640:Ion Channel Gating / Q000187:drug effects; D015993:Life Tables; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality*; D015221:Potassium Channels / Q000187:drug effects*; D013453:Sulfonylurea Compounds / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome
D007004:Hypoglycemic Agents; D007328:Insulin; D015221:Potassium Channels; D013453:Sulfonylurea Compounds